Name: | alemtuzumab |
---|---|
PubChem Substance ID: | 17396960 |
Synonyms: |
D02802; Alemtuzumab (USAN); Alemtuzumab; 216503-57-0; Campath (TN); Campath
|
Name: | alemtuzumab |
---|---|
Name (isomeric): | DB00087 |
Drug Type: | biotech |
Brand: | MabCampath, Campath (ILEX Pharmaceuticals LP), Campath |
Category: | Antineoplastic Agents |
CAS number: | 216503-57-0 |
Indication: | Alemtuzumab (Campath) is a monoclonal antibody therapy used for treatment of B-cell chronic lymphocytic leukemia. |
---|---|
Pharmacology: |
Campath is used to treat leukemia by exploiting antibody mediated lysis of CD52 presenting cells. The CD52 antigen is a cell surface protein found on essentially all B and T lymphocytes, a majority of monocytes, macrophages and most granulocytes. The CD52 antigen is not present on erythrocytes or hematopoetic stem cells. In leukemia there is an exc...
show more » |
Mechanism of Action: | Campath binds to the CD52 antigen present on most B and T lymphocytes. This binding leads to antibody-dependent lysis of leukemic cells. |
Biotransformation: | Most likely removed by opsonization via the reticuloendothelial system when bound to B or T lymphocytes |
Half Life: | ~288 hrs |
Drug interaction: |
|
---|